School of Medical, Indigenous, and Health Sciences, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales, Australia.
Clinical Nutrition Unit, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy.
J Ren Nutr. 2023 Nov;33(6S):S30-S39. doi: 10.1053/j.jrn.2022.12.004. Epub 2023 Aug 25.
There is increasing interest in the therapeutic potential of manipulating the gut microbiome of patients with chronic kidney disease (CKD). This is because there is a substantial deviation from a balanced gut microbiota profile in CKD, with many deleterious downstream effects. Nutritional interventions such as plant-based diets with reduced animal protein intake and the use of probiotics, prebiotics, and synbiotics may alter the microbiome. This article aims to briefly describe what is known about the gut microbiome in patients with CKD, factors contributing to gut dysbiosis, and outline important evidence gaps. Future potential therapies, including restoring the microbiota with food and microbiota-based and metabolomic-based therapies, are also discussed.
人们对通过操纵慢性肾脏病 (CKD) 患者的肠道微生物组来治疗疾病的潜力越来越感兴趣。这是因为 CKD 患者的肠道微生物组存在严重失衡,会产生许多有害的下游影响。营养干预措施,如减少动物蛋白摄入的植物性饮食和使用益生菌、益生元和合生菌,可能会改变微生物组。本文旨在简要描述 CKD 患者的肠道微生物组、导致肠道菌群失调的因素,以及概述重要的证据空白。还讨论了未来潜在的治疗方法,包括通过食物和基于微生物组和代谢组学的治疗来恢复微生物组。